Related Experiment Videos
Surgery from a US perspective
J B Dekernion1, J R Franklin, A Belldegrun
1Department of Surgery, UCLA School of Medicine, USA.
Cancer Surveys
|January 1, 1995
Summary
Radical prostatectomy can cure organ-confined prostate cancer in men with a long life expectancy. Early detection using prostate-specific antigen (PSA) improves outcomes and disease-free survival rates.
Area of Science:
- Urology
- Oncology
- Surgical Oncology
Background:
- Prostate screening enables early detection of organ-confined prostate carcinoma.
- Radical prostatectomy is a treatment option for localized prostate cancer, aiming to minimize morbidity and mortality.
Purpose of the Study:
- To evaluate the efficacy and outcomes of radical prostatectomy for organ-confined prostate cancer.
- To assess the impact of prostate-specific antigen (PSA) monitoring on disease-free survival.
Main Methods:
- Retrospective analysis of patients with clinically localized prostate cancer treated with radical retropubic prostatectomy and lymph node dissection.
- Monitoring of disease progression using prostate-specific antigen (PSA) concentrations.
Main Results:
- 5 and 10-year crude survival rates were 96% and 86% respectively.
- Tumor penetration of the prostatic capsule and seminal vesicle involvement significantly compromised survival.
- Patients diagnosed and treated more recently showed improved disease-free survival due to earlier PSA detection.
- 92% of patients with pathologically organ-confined tumors were disease-free with undetectable PSA at 5 years.
Conclusions:
- Radical prostatectomy can effectively cure organ-confined prostate cancer with acceptable morbidity.
- Early detection and treatment, particularly in younger patients, significantly benefit from radical prostatectomy for prostate cancer eradication.